non alcoolique – Englisch-Übersetzung – Keybot-Wörterbuch

Spacer TTN Translation Network TTN TTN Login Français English Spacer Help
Ausgangssprachen Zielsprachen
Keybot      64 Ergebnisse   19 Domänen
  www.haeberle.de  
non-alcoolique
Extra Virgin
  2 Treffer www.ogico.co.jp  
Bière, Non alcoolique 330ml
Beer, Non_alcoholic 330ml
  5 Treffer www.hivnet.ubc.ca  
CTNPT 024 : Stéatohépatite non alcoolique en présence de mono-infection par le VIH
CTNPT 024: Non-alcoholic steatohepatitis in HIV mono-infection
  aftownmusic.com  
Face à ce défi de la prévention, VALBIOTIS développe une nouvelle approche, complémentaire des recommandations actuelles, basée sur des produits capables de diminuer des facteurs de risque de ces maladies. Aujourd’hui, la prévention du diabète de type 2, de la NASH (stéatohépatite non alcoolique), de l’obésité et des dyslipidémies constitue le cœur d’expertise de VALBIOTIS.
Facing the prevention challenge, VALBIOTIS develops another approach based on products that reduce disease risk factors, to complement current recommendations. Today, preventing type 2 diabetes, NASH, (non-alcoholic steatohepatitis), obesity and dyslipidemia is the core expertise of VALBIOTIS.
  6 Treffer www.cancer.ca  
Stéatohépatite non alcoolique (NASH)
Non-alcoholic steatohepatitis (NASH)
  cute.finna.fi  
Je m'appelle Serhii Tverezovskiy et j'ai 19 ans. Je vis à Munich maintenant, mais je viens d'Ukraine, Odessa. Je suis un non-fumeur, non-alcoolique, sain, tolérant, travailleur, ponctuel, aucun tardif, aime cuisiner. Je
My name is Serhii Tverezovskiy and I am 19 years old. I live in Munich now, but I'm from Ukraine, Odessa. I am a non-smoker, non-alcoholic, healthy, tolerant, hardworking, punctual, no late risers, like to cook. I am young,
  mixoglace.com  
La Dre Jimenez-Rivera concentre sa recherche sur les maladies du foie, plus particulièrement sur la prévalence de la stéatose hépatique non alcoolique chez les enfants obèses et sur les risques de développer ce trouble.
Dr. Jimenz-Rivera’s research is focused on liver disease; specifically, the prevalence of non-alcoholic fatty liver disease in obese children, and the identification of risk factors for the occurrence of this condition. Another ongoing study relates to incidence and prevalence of autoimmune hepatitis in childhood across Canada. This study aims to describe clinical presentation and management of this condition and outcomes.
  3 Treffer www.enternext.biz  
Valbiotis est une société biopharmaceutique spécialisée dans la recherche et le développement de produits préventifs et thérapeutiques basés sur des complexes polymoléculaires indiqués à des stades précis d’évolution de pathologies métaboliques chroniques telles que le diabète de type 2, l’obésité, la dyslipidémie ou encore le NASH (Stéatose Hépatique Non-Alcoolique).
Valbiotis is a biopharmaceutical company specializing in the research and development of preventive and therapeutic products based on polymolecular complexes indicated at specific stages of progression of chronic metabolic pathologies such as type 2 diabetes, obesity, dyslipidemia or NASH (Non-Alcoholic Steatosis Hepatic).
  18 Treffer www.aa.org  
En novembre 1975, Lois W. et Tom S. (ancien administrateur qui préside le comité des archives), de Jacksonville, en Floride, inaugurent les Archives AA au BSG de New York. Dans un bref discours, John L. Norris indique que le mouvement doit continuellement se renouveler en retournant aux sources. Il rappelle que Bill disait souvent que le Conseil et le BSG « devraient consigner par écrit tout ce qu'ils font ». L'archiviste est une non-alcoolique, Nell Wing (ci-contre), qui fut longtemps la secrétaire de Bill et qui est « à elle seule une encyclopédie vivante de connaissances sur les AA ».
In November 1975, Lois W. and Tom S. of Jacksonville, Florida (a trustee who chairs the archives committee), cut a blue ribbon to officially open the A.A. Archives at G.S.O. New York. In a brief speech, Dr. John L. Norris points out that A.A. must continually renew itself by going back to its source, recalling Bill W.’s frequent request that the Board and G.S.O. “should put everything they do on the record.” The archivist is nonalcoholic Nell Wing (right), who served as Bill’s secretary for many years and is described as a “one-woman walking encyclopedia of A.A. lore.”
  www.companys.com  
La stéatose hépatique non alcoolique touche 20% de la population et on ne comprend pas son mécanisme d'apparition. Des études menées chez la souris découvrent le rôle que peut jouer PPARalpha, une protéine naturelle du foie.
Non-alcoholic fatty liver disease (NAFLD) affects 20% of the population but the onset mechanism of the disease still remains unknown. Studies in mice are helping uncover the potential role of PPAR-alpha, a natural protein found in the liver. Its absence leads to the development of the disease. Microbiota play an important role influencing the activity of the protein. These fundamental studies are essential to the discovery of treatments against fatty liver disease.
  www.dfait.gc.ca  
Les jours de grande chaleur, vous pourriez essayer la soupe borch (si vous aimez les betteraves), Cepelinai Zeppelin (gros beignets faits de pommes de terre et de viande hachée), Kugelis-kugel, des crêpes Zemaitiski (crêpes de pommes de terre à la viande), des viandes fumées, du poulet, du poisson (hareng), du mouton (ou porc, poulet, etc.) grillé saluki en brochettes, accompagnés de salades mixtes (tomates, concombres, oignons verts...), de salades blanches (à la pomme de terre), de salades rouges (betteraves, haricots, cornichons...). Comme boisson, vous pourriez prendre de la Gira (boisson sûre, faite maison à partir de pain noir et de levure) non alcoolique.
Dinner is usually from 2 to 4pm. For dinner: soup, main dish usually potatoes and meat, vegetables (usually according to the season, even though there is a variety of veggies available throughout the year). On a hot day you might try cold borch (if you like beets), Cepelinai Zeppelin (big dumplings made of potato dough and minced meat, Kugelis-kugel, Zemaitiski pancakes (potatoes pancakes with meat), Lots of smoked meat, chicken, fish: Herring, Saluki grilled mutton (pork, chicken)-shish kabobs. Mixed salad (tomatoes, cucumber, green onion...), White salad (like potato salad), Red salad (beets, beans, pickles...). Gira- a non-alcoholic sour drink, home made from dry black bread and yeast. Supper is a bit lighter. From 6 to 8 pm.
  2 Treffer hera.org.mk  
Inventiva, cotée sur Euronext Paris (IVA), est une société de biotechnologie spécialisée dans le développement de traitements innovants pour les maladies fibrotiques orphelines, telles que la stéatohépatite non alcoolique (NASH), la sclérodermie systémique (SSc) et les mucopolysaccharidoses (MPS).
• Sofinnova Partners invested €10 M in the capital increase. • Funds will be used to advance the clinical programs of the company’s portfolio compounds. • A representative of Sofinnova Partners shall be designated at the Board of directors of Inventiva. Paris, France, April 19th. 2018 – Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced today is led Inventiva Pharma (IVA) €35,5 M capital increase through its newly created Sofinnova Crossover I Fund. Sofinnova Partners invested €10 M, becoming one of the company’s largest investors. Inventiva, listed on Euronext Paris (IVA), is a biopharmaceutical company specialized in the development of treatments for fibroticand orphan diseases, such as Non Alcoholic Steato Hepatitis (NASH), systemic scleroderma (SSc) and mucopolysaccharidosis (MPS). Inventiva has a strong technology platform built on its extensive knowledge of the mechanisms of fibrosis, a chemical library of over 240,000 molecules and cell models, including patient cells, helping accelerate the discovery of new mechanisms and therapeutic candidates for the treatment of fibrotic diseases, orphan diseases and cancers. Funds raised will allow Inventiva to advance its portfolio of compounds in the clinic, in particular its lead compound, lanifibranor, through preparatory studies towards a Phase III trial for the treatment of NASH, a growing liver disease that affects more than 30 million people in the United States, and of systemic sclerosis an orphan disease with high unmet medical needs. Funds will also allow Inventiva to advance its second program, odiparcil, a drug candidate for the treatment of multiple forms of mucopolysaccharidosis. Jacques Theurillat, Partner in the Sofinnova Crossover I Fund, commented: « Inventiva is exactly the type of company we are seeking to invest in with our Crossover fund: innovative technology addressing diseases of high unmet medical need with large market sizes, an experimented team backed by a prestigious international investor syndicate helping the company develop its global ambitions ». Press contact for Sofinnova Partners Anne Rein Tel: +33 6 03 35 92 05 e-mail: anne.rein@strategiesimage.com